Common community respiratory viruses in patients with cancer: more than just "common colds". (Q35122262)

6 August 2017

1 reference

title

Common community respiratory viruses in patients with cancer: more than just "common colds". (English)

1 reference

6 August 2017

author

Dimitrios P Kontoyiannis

series ordinal

3

object named as

Dimitrios P Kontoyiannis

1 reference

6 August 2017

Krystal L Hicks

1

1 reference

6 August 2017

Roy F Chemaly

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

6 August 2017

number of pages

12

1 reference

inferred from page(s)

published in

Cancer

1 reference

6 August 2017

volume

97

1 reference

6 August 2017

issue

10

1 reference

6 August 2017

page(s)

2576-2587

1 reference

Evaluation of four methods for the diagnosis of respiratory syncytial virus infection in older adults

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

Acute respiratory tract infection in daycare centers for older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

Treatment of influenza A (H1N1) virus infection with ribavirin aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus infection in immunocompromised adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory viral infections in immunocompetent and immunocompromised persons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus and parainfluenza virus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Community respiratory virus infections in immunocompromised patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Parainfluenza Virus Respiratory Infection after Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Prophylaxis and treatment of influenza

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Impact of respiratory virus infections on persons with chronic underlying conditions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory virus infections in stem cell transplant patients: the European experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Community respiratory virus infections among hospitalized adult bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Variation of influenza A, B, and C viruses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Parainfluenza virus type 4 infections in pediatric patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Differing virulence of H1N1 and H3N2 influenza strains

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

State of the art: bronchiolitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

An outbreak of respiratory syncytial virus in a bone marrow transplant center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus infection following hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Infection control of nosocomial respiratory viral disease in the immunocompromised host

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Community respiratory virus infections in bone marrow transplant recipients: the M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Viral infections in leukemia and bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial viral infection in children with compromised immune function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybrid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Prevention and treatment of influenza in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Design of aromatic inhibitors of influenza virus neuraminidase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Ribavirin small-particle aerosol treatment of influenza

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Ribavirin Aerosol Treatment of Influenza B Virus Infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Combination antiviral therapy for respiratory virus infections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

What link between early respiratory viral infections and atopic asthma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11353

7 January 2021

Identifiers

DOI

10.1002/CNCR.11353

1 reference

6 August 2017

1 reference